Drug Database
Back to search

Poland· PL-100429645

Adenocor

A adenosine product containing adenosinum, registered in Poland by InPharm Sp. z o.o.. The same ATC class is registered in 16 of our 19 countries.

ATC C01EB10

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedAdenocorATCC01EB10REGISTER NO.PL-100429645PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about adenosinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Adenosine is registered in 16 of 19 countries.

Countries holding a registration under ATC C01EB10 (adenosine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search adenosine products by name

Adenosine · ATC C01EB10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Adenosinum
Manufacturer
InPharm Sp. z o.o.
Country
Poland (PL)
ATC code
C01EB10
ATC class
Adenosine
Defined daily dose
15 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05909991421632

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

181 interactions on record for adenosine.

Graded by severity as the source publishes them — 38 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check adenosine against other medicinesHow interaction checks work

Adenosine · interactions on record

181 records

  • 38 severe
  • 90 moderate
  • 1 minor
  • 52 info

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • PapaverinC04AX38severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Adenosine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All adenosine products

Authorised across Europe · EMA

The same active substance is authorised in 22 EEA countries. Names it is sold under:

  • Austria · Adenosin Baxter, Adenosin Hikma
  • Belgium · Adenocor, Adenosine Fresenius Kabi
  • Cyprus · Caden
  • Czechia · Adenocor
  • Germany · Adenoscan, Adenosin Altamedics
  • Denmark · Adenocor, Adenosin Fresenius Kabi
  • Estonia · Adenosin Life Medical
  • Spain · Adenocor, Adenoscan
  • Finland · Adenosin Life Medical, Adenosin Macure
  • France · Adenoscan, Adenosine Hikma
  • United Kingdom (Northern Ireland) · Adenocor, Adenoscan
  • Greece · Adenorythm
  • Hungary · Adenocor
  • Ireland · Adenocor, Adenosine
  • Italy · Adenoscan, Adenosina Hikma
  • Lithuania · Adenosine Life Medical
  • Luxembourg · Adenocor
  • Netherlands · Adenocor, Adenosine Fresenius Kabi
  • Norway · Adenosin Life Medical, Adenosin Macure
  • Portugal · Adenoscan, Adenosina Baxter
  • Sweden · Adenosin Life Medical, Adenosin Macure
  • Slovakia · Adenocor

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c48eef43-6c84-4919-92c2-21d8d29cc97b
GET /v1/drugs/c48eef43-6c84-4919-92c2-21d8d29cc97b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "3 mg/ml",
  "packaging": "05909991421632 ¦ Lz ¦ 135054\n6 fiol. 2 ml",
  "substance": "Adenosinum 3 mg/ml",
  "common_name": "Adenosinum",
  "pl_product_id": "100429645",
  "pozwolenie_nr": "4/20",
  "auth_procedure": "IR",
  "authorisation_validity": "2025-01-13"
}
API referenceMCP serverPlans

See everything about adenosine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console